BPC-157 (10mg vials)
Product Format |
10mg vials |
Vial Size |
10mg |
Vial Capacity |
3 mL |
Box Combinations |
20mg, 50mg, 100mg, 200mg |
Cost per milligram |
$3.90 – $5.30 |
Multi-vial Purity |
99.66% |
Purity Screening |
PASSED |
Doubly Validated |
YES |
Independently Tested |
YES |
Peptide Partners Manufacturer Id: VI32
Batch Id: BC202604
Research Studies
(for educational purposes only)
Study 1: Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
Authors: Chung-Hsun Chang, Wen-Chung Tsai, Ya-Hui Hsu, and Jong-Hwei Su Pang
Source: https://www.mdpi.com/1420-3049/19/11/19066
Scientific Findings
This in vitro study investigated the effects of BPC 157 on rat Achilles tendon fibroblasts. The researchers found that BPC 157 significantly upregulated the expression of the growth hormone (GH) receptor at both the mRNA and protein levels in a dose- and time-dependent manner. This upregulation of the GH receptor potentiated the proliferative effects of growth hormone, as evidenced by increased cell proliferation (MTT assay) and proliferating cell nuclear antigen (PCNA) expression. Furthermore, the study demonstrated that the addition of growth hormone to BPC 157-treated fibroblasts activated Janus kinase 2 (JAK2), a key downstream signaling molecule in the GH receptor pathway. These findings suggest that BPC 157 promotes tendon healing by enhancing the sensitivity of tendon fibroblasts to growth hormone, thereby amplifying its anabolic effects.
Plain English Interpretation
Scientists studied how the peptide BPC-157 affects tendon cells in a lab. They discovered that BPC-157 makes tendon cells more responsive to growth hormone, a natural substance in our bodies that helps with growth and repair. By increasing the number of ‘docking sites’ for growth hormone on the surface of these cells, BPC-157 helps them multiply faster when growth hormone is present. This suggests that BPC-157 could help tendons heal more effectively by boosting the natural healing process driven by growth hormone.
Study 2: Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Authors: Ming-Jer Hsieh, Hsien-Ta Liu, Chao-Nin Wang, Hsiu-Yun Huang, Yuling Lin, Yu-Shien Ko, Jong-Shyan Wang, Vincent Hung-Shu Chang, Jong-Hwei S Pang
Source: https://pubmed.ncbi.nlm.nih.gov/27847966/
Scientific Findings
This study elucidated the pro-angiogenic mechanism of BPC 157 in vitro and in vivo. In vitro, BPC 157 was shown to increase endothelial tube formation in human umbilical vein endothelial cells (HUVECs). This effect was associated with the upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) expression at both the mRNA and protein levels. BPC 157 also promoted the internalization of VEGFR2, a critical step for receptor activation. The study further demonstrated that BPC 157 time-dependently activated the downstream VEGFR2-Akt-eNOS signaling pathway. Inhibition of endocytosis with dynasore blocked both VEGFR2 internalization and the pro-angiogenic effects of BPC 157, confirming the essential role of this process. These findings indicate that BPC 157 exerts its pro-angiogenic effects by increasing VEGFR2 expression and promoting its internalization and subsequent activation of the VEGFR2-Akt-eNOS signaling cascade.
Plain English Interpretation
In this study, scientists investigated how BPC-157 promotes the formation of new blood vessels. They found that in a lab setting, BPC-157 encourages the cells that line blood vessels to form tube-like structures, a key step in creating new vessels. The researchers discovered that BPC-157 achieves this by increasing the number of a specific type of ‘receiver’ (called VEGFR2) on the surface of these cells. It also helps these receivers move inside the cell, which turns on a signaling pathway that tells the cell to start building new blood vessels. This study reveals a key mechanism by which BPC-157 may help with healing and tissue repair by improving blood supply.
Study 3: Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway
Authors: Ming-Jer Hsieh, Cheng-Hung Lee, Ho-Yen Chueh, Gwo-Jyh Chang, Hsiu-Yun Huang, Yuling Lin & Jong-Hwei S. Pang
Source: https://www.nature.com/articles/s41598-020-74022-y
Scientific Findings
This study investigated the molecular mechanisms by which BPC 157 modulates vasomotor tone. Using isolated rat aorta, the researchers demonstrated that BPC 157 induced a concentration-dependent vasodilation that was endothelium-dependent and mediated by nitric oxide (NO). In vitro experiments with vascular endothelial cells showed that BPC 157 stimulated NO production, which in turn promoted cell migration. The study further elucidated the signaling pathway involved, showing that BPC 157 enhanced the phosphorylation of Src, Caveolin-1 (Cav-1), and endothelial nitric oxide synthase (eNOS). Inhibition of Src abolished these effects, confirming its upstream role. Co-immunoprecipitation analysis revealed that BPC 157 reduced the inhibitory binding between Cav-1 and eNOS, thereby activating eNOS. These findings indicate that BPC 157 modulates vasomotor tone by inducing NO generation through the activation of the Src-Cav-1-eNOS signaling pathway.
Plain English Interpretation
In this research, scientists explored how BPC-157 affects the widening of blood vessels. They found that BPC-157 causes blood vessels to relax and widen, and that this effect depends on the inner lining of the blood vessel and a molecule called nitric oxide. In lab experiments, BPC-157 was shown to trigger the production of nitric oxide in the cells lining the blood vessels, which then encourages these cells to move. The study also identified a specific chain of events, or signaling pathway, that BPC-157 activates to produce nitric oxide. By activating this pathway, BPC-157 essentially ‘flips a switch’ that leads to the widening of blood vessels. This could be important for its healing properties, as wider blood vessels can deliver more blood, oxygen, and nutrients to injured tissues.
Storage:
All of our manufacturing partners produce peptides using the Lyophilization (Freeze Drying) process, ensuring products maintain stability for shipping and storage for 12+ months.
In lyophilized form, they are shelf-stable for many weeks. However, for long-term storage, it is recommended to store them in the freezer.
We often hear concerns about the standard “discard after 28 days of first use” disclaimer. Don’t worry, this has nothing to do with studies regarding the efficacy of specific peptides. 28 days is the FDA requirement for producers of multi-use vials to prove their bacteriostatic maintains efficacy. This minimum requirement becomes the de facto standard.
In our experience, if you use proper sterile procedures and refrigerated storage, you can continue sampling from the same reconstituted vial for 3+ months.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
Purity |
Laboratory |
Double Validated |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-07-02 |
99.71% |
Kovera |
||
|
Reconstitution Solution |
BAC202606 |
WF03 |
2026-07-13 |
99.9% |
Kovera |
||
|
Retatrutide |
RTT2613 |
WF03 |
2026-07-02 |
99.77% |
Kovera |
||
|
PT-141 |
PT202605 |
VI32 |
2026-06-25 |
99.74% |
Kovera |
||
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-19 |
99.80% |
TrustPointe |
||
|
KPV |
KV202606 |
WF03 |
2026-06-12 |
99.36% |
TrustPointe |
Yes |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-12 |
99.82% |
TrustPointe |
Yes |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-12 |
99.98% |
TrustPointe |
Yes |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-12 |
99.96% |
TrustPointe |
Yes |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
99.36% |
Kovera |
Yes |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-10 |
99.88% |
TrustPointe |
Yes |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
99.74% |
Kovera |
Yes |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
99.71% |
Kovera |
Yes |
|
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
99.76% |
Kovera |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
99.55% |
Kovera |
Yes |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
99.68% |
Kovera |
Yes |
|
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
99.70% |
Kovera |
Yes |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-10 |
99.34% |
TrustPointe |
Yes |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-09 |
99.65% |
Kovera |
Yes |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-09 |
99.90% |
Kovera |
Yes |
|
|
NAD+ |
NDB202606 |
WF03 |
2026-05-28 |
99.55% |
TrustPointe |
||
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-13 |
99.67% |
TrustPointe |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-13 |
99.86% |
Kovera |
||
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-13 |
99.78% |
Kovera |
Yes |
|
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-29 |
99.53% |
Chromate |
Yes |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-11 |
99.22% |
TrustPointe |
Yes |
|
|
MOTS-c |
MC202605 |
WF03 |
2026-06-08 |
99.98% |
TrustPointe |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-08 |
99.94% |
TrustPointe |
Yes |
|
|
TB-500 (TB4) |
TB202605 |
WF03 |
2026-05-28 |
99.76% |
TrustPointe |
||
|
Tesamorelin |
TES202605 |
WF03 |
2026-05-28 |
99.81% |
TrustPointe |
||
|
Retatrutide |
RT202605 |
WF03 |
2026-05-27 |
99.75% |
TrustPointe |
||
|
Reconstitution Solution |
BAC202602 |
VI32 |
2026-05-14 |
99.90% |
Kovera |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
99.93% |
TrustPointe |
||
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-14 |
99.74% |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-05-14 |
99.73% |
TrustPointe |
Yes |
|
|
GHK-Cu |
CU202604 |
WF03 |
2026-05-14 |
99.74% |
TrustPointe |
Yes |
|
|
BPC-157 |
BC202604 |
VI32 |
2026-05-13 |
99.72% |
TrustPointe |
Yes |
|
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
99.82% |
Kovera |
||
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-21 |
99.85% |
Kovera |
||
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
99.81% |
Kovera |
||
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
99.90% |
Kovera |
Yes |
|
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
99.86% |
Kovera |
||
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
99.93% |
Kovera |
||
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-14 |
99.90% |
Kovera |
||
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
99.96% |
Kovera |
||
|
Retatrutide |
RT202604 |
WF03 |
2026-04-16 |
99.54% |
TrustPointe |
||
|
Sermorelin |
SER202601 |
VI32 |
2026-04-01 |
99.94% |
Kovera |
||
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
99.96% |
Kovera |
||
|
GHK-Cu |
CU202604 |
WF03 |
2026-04-03 |
99.93% |
Kovera |
Yes |
|
|
SS-31 |
SS202601 |
WF03 |
2026-04-03 |
99.82% |
TrustPointe |
||
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
99.91% |
Kovera |
||
|
Retatrutide |
RT202603 |
WF03 |
2026-03-30 |
99.40% |
TrustPointe |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-25 |
99.88% |
Kovera |
||
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-27 |
99.89% |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-03-27 |
99.63% |
TrustPointe |
||
|
Tesamorelin |
TES202603 |
WF03 |
2026-03-25 |
99.52% |
TrustPointe |
||
|
BPC-157 |
BC202604 |
VI32 |
2026-03-18 |
99.60% |
TrustPointe |
Yes |
|
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202602 |
WF03 |
2026-02-27 |
99.92% |
TrustPointe |
||
|
Thymosin Alpha-1 |
TA202602 |
WF03 |
2026-02-25 |
99.95% |
Kovera |
||
|
KLOW |
KW202602 |
WF03 |
2026-03-01 |
99.86% |
Chromate |
||
|
NAD+ |
NDB202601 |
VI32 |
2026-02-07 |
99.92% |
Kovera |
||
|
SS-31 |
SS202602 |
WF03 |
2026-02-08 |
99.68% |
Chromate |
||
|
MOTS-c |
MC202602 |
WF03 |
2026-02-09 |
99.41% |
Chromate |
||
|
Selank |
SEK202601 |
VI32 |
2026-01-29 |
99.94% |
Chromate |
||
|
Unbuffered NAD+ |
NDU202601 |
MZ21 |
2026-01-20 |
99.85% |
Chromate |
||
|
KPV |
KV202601 |
VI32 |
2026-01-20 |
99.90% |
Chromate |
||
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-14 |
99.92% |
TrustPointe |
||
|
TB500 (TB4) |
TB202601 |
WF03 |
2026-01-14 |
99.86% |
TrustPointe |
||
|
Retatrutide |
RT202602 |
WF03 |
2026-01-13 |
99.63% |
TrustPointe |
||
|
PT-141 |
PT202512 |
VI32 |
2026-01-12 |
99.89% |
BioRegen |
||
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-10 |
99.70% |
TrustPointe |
||
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-10 |
99.33% |
TrustPointe |
||
|
Tesamorelin |
TES202601 |
WF03 |
2025-12-29 |
99.71% |
TrustPointe |
||
|
BPC-157 |
BP202512 |
WF03 |
2025-12-29 |
99.46% |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2025-12-29 |
99.64% |
TrustPointe |
||
|
GHK-Cu |
GK202512 |
SH07 |
2025-12-19 |
99.79% |
BioRegen |
||
|
MOTS-c |
MC202512 |
WF03 |
2025-12-22 |
99.89% |
BioRegen |
||
|
Retatrutide |
RP260130 |
VI32 |
2025-12-22 |
99.72% |
TrustPointe |
||
|
SS-31 |
SS202512 |
WF03 |
2025-12-19 |
99.70% |
TrustPointe |
||
|
Retatrutide |
RP202601 |
DF05 |
2025-12-22 |
99.63% |
TrustPointe |
||
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202512 |
WF03 |
2025-12-09 |
99.80% |
TrustPointe |
||
|
Retatrutide |
RP202511 |
DF05 |
2025-12-19 |
99.73% |
TrustPointe |
||
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-10 |
99.33% |
TrustPointe |
||
|
Retatrutide |
RP20251001 |
DF05 |
2025-10-13 |
99.86% |
TrustPointe |
||
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-10-03 |
99.74% |
TrustPointe |
||
|
Retatrutide |
RP20250929 |
VI32 |
2025-10-03 |
99.47% |
TrustPointe |
||
|
Humanin |
HP20250805 |
WF03 |
2025-09-19 |
99.92% |
BioRegen |
||
|
MOTS-c |
YC20250807 |
WF03 |
2025-09-19 |
99.87% |
BioRegen |
||
|
DSIP |
DS20250820 |
SH07 |
2025-09-19 |
99.88% |
BioRegen |
||
|
SS-31 |
SY20250806 |
WF03 |
2025-09-19 |
99.70% |
BioRegen |
||
|
CJC/Ipamorelin |
CI20250805 |
WF03 |
2025-09-11 |
99.84% |
TrustPointe |
||
|
BPC-157 |
BP20250808 |
WF03 |
2025-09-05 |
99.99% |
TrustPointe |
||
|
Sermorelin |
SM20250723 |
WF03 |
2025-08-27 |
99.84% |
BioRegen |
||
|
Tesamorelin |
TS20250722 |
WF03 |
2025-08-22 |
99.10% |
TrustPointe |
||
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-08-20 |
99.43% |
TrustPointe |
||
|
Semaglutide |
SM20250801 |
EJ12 |
2025-08-20 |
99.34% |
TrustPointe |
||
|
Ipamorelin |
IP20250721 |
WF03 |
2025-08-15 |
99.64% |
TrustPointe |
||
|
GHK-Cu |
CU20250717 |
SH07 |
2025-08-09 |
99.73% |
BioRegen |
||
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-08-08 |
99.41% |
TrustPointe |
||
|
NAD+ |
ND20250503 |
SH07 |
2025-07-31 |
99.76% |
BioRegen |
||
|
VIP |
VP20250511 |
SH07 |
2025-07-31 |
99.42% |
BioRegen |
||
|
Retatrutide |
CD20250708 |
SH07 |
2025-07-25 |
99.42% |
TrustPointe |
||
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-07-17 |
99.52% |
TrustPointe |
||
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-07-17 |
99.68% |
TrustPointe |
Current Endotoxin Certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
USP Conformation |
Laboratory |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-06-30 |
Conforms |
Kovera |
|
|
Reconstitution Solution |
BAC202606 |
WF03 |
2026-07-13 |
Conforms |
Kovera |
|
|
Retatrutide |
RTT2613 |
WF03 |
2026-06-30 |
Conforms |
Kovera |
|
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-22 |
Conforms |
TrustPointe |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-15 |
Conforms |
TrustPointe |
|
|
PT-141 |
PT202605 |
VI32 |
2026-06-12 |
Conforms |
Kovera |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Conforms |
Kovera |
|
|
MOTS-c |
MC202605 |
WF03 |
2026-06-11 |
Conforms |
TrustPointe |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
Conforms |
Kovera |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
|
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
|
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
Conforms |
Kovera |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
Conforms |
Kovera |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-09 |
Conforms |
Kovera |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-11 |
Conforms |
TrustPointe |
|
|
Epithalon |
ET202604 |
WF03 |
2026-05-13 |
Conforms |
Kovera |
|
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-13 |
Conforms |
Kovera |
|
|
NAD+ |
NDB202606 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
|
|
TB-500 (TB4) |
TB202605 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
|
|
Tesamorelin |
TES202605 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RT202605 |
WF03 |
2026-05-27 |
Conforms |
TrustPointe |
|
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
Conforms |
TrustPointe |
|
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-18 |
Conforms |
TrustPointe |
|
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-18 |
Conforms |
TrustPointe |
|
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
Conforms |
Kovera |
|
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
|
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
Conforms |
Kovera |
|
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Conforms |
Kovera |
|
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
|
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
Conforms |
Kovera |
|
|
Retatrutide |
RT202604 |
WF03 |
2026-04-16 |
Conforms |
TrustPointe |
|
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
Conforms |
Kovera |
|
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
|
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-14 |
Conforms |
Kovera |
|
|
Sermorelin |
SER202601 |
VI32 |
2026-04-01 |
Conforms |
Kovera |
|
|
GHK-Cu |
CU202604 |
WF03 |
2026-04-03 |
Conforms |
Kovera |
|
|
SS-31 |
SS202601 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
|
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
Conforms |
Kovera |
|
|
Retatrutide |
RT202603 |
WF03 |
2026-03-30 |
Conforms |
TrustPointe |
|
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-25 |
Conforms |
Kovera |
|
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-27 |
Conforms |
TrustPointe |
|
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-03-26 |
Conforms |
TrustPointe |
|
|
Tesamorelin |
TES202603 |
WF03 |
2026-03-25 |
Conforms |
TrustPointe |
|
|
SS-31 |
SS202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
KLOW Blend |
KW202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
BPC-157 |
BC202604 |
WF03 |
2026-03-17 |
Conforms |
Kovera |
|
|
Thymosin Alpha-1 |
TA202601 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
|
|
MOTS-c |
MC202602 |
WF03 |
2026-02-08 |
Conforms |
Kovera |
|
|
NAD+ |
NDB202601 |
VI32 |
2026-02-08 |
Conforms |
Kovera |
|
|
Unbuffered NAD+ |
NDU202601 |
MZ21 |
2026-01-28 |
Conforms |
TrustPointe |
|
|
KPV |
KV202601 |
VI32 |
2026-01-28 |
Conforms |
TrustPointe |
|
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
|
|
TB500 |
TB202601 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RT202602 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
|
|
PT-141 |
PT202512 |
VI32 |
2026-01-07 |
Conforms |
BioRegen |
|
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-10 |
Conforms |
TrustPointe |
|
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-10 |
Conforms |
TrustPointe |
|
|
Tesamorelin |
TES202601 |
WF03 |
2026-01-06 |
Conforms |
TrustPointe |
|
|
BPC-157 |
BP202512 |
WF03 |
2025-12-30 |
Conforms |
TrustPointe |
|
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2025-12-30 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP260130 |
DF05 |
2025-12-22 |
Conforms |
TrustPointe |
|
|
SS-31 |
SS202512 |
WF03 |
2025-12-19 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP202601 |
DF05 |
2025-12-22 |
Conforms |
TrustPointe |
|
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202512 |
WF03 |
2025-12-08 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP202511 |
DF05 |
2025-11-10 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-10 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP20251001 |
DF05 |
2025-10-13 |
Conforms |
TrustPointe |
|
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-10-03 |
Conforms |
TrustPointe |
|
|
Retatrutide |
RP20250929 |
VI32 |
2025-10-03 |
Conforms |
TrustPointe |
|
|
Humanin |
HP20250805 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
|
|
MOTS-c |
YC20250807 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
|
|
DSIP |
DS20250820 |
SH07 |
2025-09-19 |
Conforms |
BioRegen |
|
|
SS-31 |
SY20250806 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
|
|
CJC/Ipamorelin |
CI20250805 |
WF03 |
2025-09-03 |
Conforms |
TrustPointe |
|
|
BPC-157 |
BP20250808 |
WF03 |
2025-09-03 |
Conforms |
TrustPointe |
|
|
Bacteriostatic Water |
BAC20250807 |
SH07 |
2025-08-27 |
Conforms |
BioRegen |
|
|
Tesamorelin |
TS20250722 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
Sermorelin |
SM20250723 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
Semaglutide |
SM20250801 |
EJ12 |
2025-08-20 |
Conforms |
TrustPointe |
|
|
Ipamorelin |
IP20250721 |
WF03 |
2025-08-11 |
Conforms |
TrustPointe |
|
|
GHK-Cu |
CU20250717 |
SH07 |
2025-08-08 |
Conforms |
TrustPointe |
|
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-08-04 |
Conforms |
TrustPointe |
|
|
NAD+ |
ND20250503 |
SH07 |
2025-07-29 |
Conforms |
TrustPointe |
|
|
VIP |
VP20250511 |
SH07 |
2025-07-29 |
Conforms |
TrustPointe |
|
|
Retatrutide |
CD20250708 |
SH07 |
2025-07-24 |
Conforms |
TrustPointe |
|
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-07-17 |
Conforms |
TrustPointe |
|
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-07-17 |
Conforms |
TrustPointe |
Current Heavy Metal Certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
Class 1 USP |
Full USP |
Laboratory |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-07-01 |
Conforms |
Kovera |
||
|
Retatrutide |
RTT2613 |
WF03 |
2026-07-01 |
Conforms |
Kovera |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
KPV |
KV202606 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
BPC-157 |
BC202607 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
||
|
Semaglutide |
SM202607 |
VI32 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RT202607 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
MOTS-c |
MC202605 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
||
|
PT-141 |
PT202605 |
VI32 |
2026-06-13 |
Conforms |
Kovera |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Conforms |
Kovera |
||
|
Semaglutide |
SM202607 |
VI32 |
2026-06-11 |
Conforms |
Kovera |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
KPV |
KV202606 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
BPC-157 |
BC202607 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
Retatrutide |
RT202607 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Conforms |
Kovera |
||
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-14 |
Conforms |
Kovera |
||
|
NAD+ |
NDB202606 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TES202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RT202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
TB-500 |
TB202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
||
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
||
|
SS-31 |
SS202602 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
AOD-9604 |
AO202605 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
KLOW Blend |
KW202602 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-16 |
Conforms |
Kovera |
||
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-16 |
Conforms |
Kovera |
||
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-04-26 |
Conforms |
Kovera |
||
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-22 |
Conforms |
Kovera |
||
|
Pinealon |
PN202603 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
Semax |
SX202603 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
MOTS-c |
MC202602 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CG202603 |
VI32 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
SS-31 |
SS202601 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
||
|
DSIP |
DS202605 |
WF03 |
2026-04-24 |
Conforms |
Kovera |
||
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Conforms |
Kovera |
||
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
||
|
Retatrutide |
RT202604 |
WF03 |
2026-04-22 |
Conforms |
Kovera |
||
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
Conforms |
Kovera |
||
|
SS-31 |
SS202601 |
WF03 |
2026-04-02 |
Conforms |
Kovera |
||
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CG202603 |
VI32 |
2026-03-31 |
Conforms |
Kovera |
||
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
KLOW Blend |
KW202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
SS-31 |
SS202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
MOTS-c |
MC202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
||
|
Tesamorelin |
TES202603 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
||
|
Sermorelin |
SER202601 |
VI32 |
2026-03-29 |
Conforms |
Kovera |
||
|
MOTS-c |
MC202603 |
VI32 |
2026-04-01 |
Conforms |
Kovera |
||
|
Retatrutide |
RT202603 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
||
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
Conforms |
Kovera |
||
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-26 |
Conforms |
Kovera |
||
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-26 |
Conforms |
Kovera |
||
|
BPC-157 |
BC202604 |
WF03 |
2026-03-17 |
Conforms |
Kovera |
||
|
Thymosin Alpha-1 |
TA202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
||
|
NAD+ |
NDB202601 |
VI32 |
2026-02-08 |
Conforms |
Kovera |
||
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
||
|
TB500 |
TB202601 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RT202602 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
||
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-19 |
Conforms |
TrustPointe |
||
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-19 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TES202601 |
WF03 |
2026-01-19 |
Conforms |
TrustPointe |
||
|
BPC-157 |
BP202512 |
WF03 |
2026-01-08 |
Conforms |
TrustPointe |
||
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2026-01-08 |
Conforms |
TrustPointe |
||
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-12-03 |
Conforms |
TrustPointe |
||
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-11-24 |
Conforms |
TrustPointe |
||
|
BPC-157 |
BP20250808 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
GHK-Cu |
CU20250717 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Ipamorelin |
IP20250721 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Sermorelin |
SM20250723 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
SS-31 |
SY20250806 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Tesamorelin |
TS20250722 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
||
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-11-12 |
Conforms |
TrustPointe |
Current Sterility Certifications
|
Product |
Batch Id |
Manufacturer |
Date |
USP Pass/Fail |
Rapid Pass/Fail |
Laboratory |
File |
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-06-30 |
Pass |
Kovera |
||
|
Retatrutide |
RTT2613 |
WF03 |
2026-06-30 |
Pass |
Kovera |
||
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-26 |
Pass |
TrustPointe |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-26 |
Pass |
TrustPointe |
||
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-26 |
Pass |
TrustPointe |
||
|
MOTS-c |
MC202605 |
WF03 |
2026-06-23 |
Pass |
TrustPointe |
||
|
NAD+ |
NDB202606 |
WF03 |
2026-06-15 |
Pass |
TrustPointe |
||
|
Tesamorelin |
TES202605 |
WF03 |
2026-06-15 |
Pass |
TrustPointe |
||
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Pass |
Kovera |
||
|
PT-141 |
PT202605 |
VI32 |
2026-06-12 |
Pass |
Kovera |
||
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
Pass |
Kovera |
||
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
Pass |
Kovera |
||
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
Pass |
Kovera |
||
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
Pass |
Kovera |
||
|
Retatrutide |
RT202605 |
WF03 |
2026-06-12 |
Pass |
Kovera |
||
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-09 |
Pass |
Kovera |
||
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
Pass |
Kovera |
||
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
Pass |
Kovera |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-29 |
Pass |
TrustPointe |
||
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
Reconstitution Solution |
BAC202602 |
VI32 |
2026-05-14 |
Pass |
Kovera |
||
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
Pass |
Kovera |
||
|
Cagrilintide |
CG202607 |
VI32 |
2026-05-14 |
Pass |
Kovera |
||
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
Pass |
Kovera |
||
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
Pass |
– |
Kovera |
|
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Pass |
Kovera |
||
|
Retatrutide |
RT202604 |
WF03 |
2026-04-22 |
Pass |
– |
Kovera |
|
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
– |
Pass |
Kovera |
|
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
– |
Pass |
Kovera |
|
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-12 |
Pass |
– |
Kovera |
|
|
SS-31 |
SS202601 |
WF03 |
2026-04-12 |
– |
Pass |
Kovera |
|
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
Pass |
– |
Kovera |
|
|
Bacteriostatic Water |
BAC202601 |
WF03 |
2026-01-13 |
Pass |
– |
TrustPointe |
|
|
Bacteriostatic Water |
BAC20250807 |
SH07 |
2025-09-09 |
Pass |
– |
TrustPointe |
|
|
Meta-Z |
MZR20250713 |
DF05 |
2025-08-26 |
Pass |
– |
TrustPointe |
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
- USP <85> Bacterial Endotoxin Result: <x.xx EU/mL
Because it’s reported as “<x.xx” this indicates the test did not detect endotoxin above the detection limit of the cartridge. - If a result is above the limit of detection of the cartridge, it will be reported as a number (without the “<“).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
- CV stands for coefficient of variation, a measure of repeatability.
- For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
- This refers to the precision of the positive control (spiked sample).
- Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
- This tells us how much of the known endotoxin spike was recovered from your sample.
- The acceptable range is 50–200% per USP <85>
Related Products
- Reconstitution Solution (BAC, 2 x 10mL vials)
- Reconstitution Solution (BAC, 5 x 10mL vials)
- Reconstitution Solution (BAC, 10 x 10mL vials)
Browse more in Reconstitution.
Related products
